{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:36Z","timestamp":1761870276657,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.016","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T02:33:34Z","timestamp":1308796414000},"page":"280-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Monitoring of Imatinib in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission: Does Achievement of a Stable Major Molecular Response at any Time Point Identify a Privileged Group of Patients? A Multicenter Experience in Argentina and Uruguay"],"prefix":"10.1016","volume":"11","author":[{"given":"Carolina","family":"Pavlovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Giere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Negri","family":"Aranguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isolda","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Uriarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Garc\u00eda","family":"Reinoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia E.","family":"Magari\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lem","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Murro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Lastiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.016_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.016_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.03.016_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.016_bib4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.016_bib5","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate\u2013treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.016_bib6","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention to treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.016_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.016_bib8","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.016_bib9","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.016_bib10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.016_bib11","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1073\/pnas.83.9.2934","article-title":"Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization","volume":"83","author":"Pinkel","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2011.03.016_bib12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014 a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.016_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.clml.2011.03.016_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of a randomized clinical trial requiring prolonged observation of each patient","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2011.03.016_bib15","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.016_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-08-1195","article-title":"Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response","volume":"15","author":"Palandri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.016_bib17","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.016_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse","volume":"19","author":"Marin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.016_bib19","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.016_bib20","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.016_bib21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"issue":"suppl 2","key":"10.1016\/j.clml.2011.03.016_bib22","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.3816\/CLM.2007.s.003","article-title":"Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy","volume":"7","author":"Oehler","year":"2007","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:08Z","timestamp":1761870068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S2152265011000176"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Monitoring of Imatinib in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission: Does Achievement of a Stable Major Molecular Response at any Time Point Identify a Privileged Group of Patients? A Multicenter Experience in Argentina and Uruguay","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}